All In Biotech

Drug Trial Radar · NCT06120842

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

201

Actual

Start

Oct 13, 2023

Primary completion

Jan 31, 2025

Study completion Nov 2027

Sponsor

Lead sponsor
SpyGlass Pharma, Inc.Industry
Sponsor type
Industry
First posted
Nov 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a randomized study to evaluate and compare two doses of the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Conditions

  • Cataract
  • Glaucoma
  • Ocular Hypertension

Interventions

  • Bimatoprost Implant System (High Dose)Drug

    Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL

  • Bimatoprost Implant System (Low Dose)Drug

    Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL

  • Timolol Maleate Ophthalmic Solution, 0.5%Drug

    Timolol Maleate Ophthalmic Solution 0.5% BID

  • Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOLDevice

    Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

  • SpyGlass IOLDevice

    SpyGlass Intraocular Lens

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean IOP Reduction from Baseline (mmHg)Time frame: Weeks 2 and 6, and Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arizona Advanced Eye Research Institute

    Glendale, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.